Below are current clinical trials.5 studies in Polycystic kidney disease
(open studies only).
Filter this list of studies by location, status and more.
The overall objective of this study is to define genes causing cystic kidney disease and to determine the degree to which variants at these cystic kidney disease genes underlie the clinical diversity of these disorders. This will provide an insight into the disease mechanisms, and explore novel mutation screening methods. A combination of mutation screening in clinically characterized human cystic kidney disease populations, gene hunting and exploration of incompletely penetrant alleles in humans will provide a comprehensive picture of how mutations cause the resulting phenotype.
This research study is about developing a rapid, accurate urine test to help diagnose and perhaps monitor ADPKD (Autosomal Dominant Polycystic Kidney Disease).
The purpose of this study is to conduct a controlled, unblinded RCT comparing mild CR to a control diet in patients with rapidly progressive ADPKD (class 1C-E by the lrazabal classification), under conditions of standardized hydration and sodium intake, to determine whether it slows the rate of growth of the kidneys (primary endpoint), is well tolerated and safe, lowers levels of IGF-1 in serum and the excretion of inflammation (MCP-1) and fibrosis (TGF-) biomarkers in urine, improves kidney texture, slows the decline of GFR and the rate of growth of the liver, and improves the quality of life.
This research study is being done to create a collection of biospecimens (blood, urine, cyst fluid, bile, kidney or liver tissue, etc.) that can be used to facilitate the conduction of research on polycystic kidney and/or liver disease.
This Pilot study will enable development & assessment of a Polycystic Liver Disease-specific patient reported outcomes questionnaire (PLD-Q). Polycystic liver disease (PLD) is characterized by the formation of numerous cysts in the liver, and can lead to severe symptomatic hepatomegaly. It is common in patients with autosomal dominant polycystic liver disease (ADPLD) and autosomal dominant polycystic kidney disease (ADPKD).
July 13, 2017
- Polycystic kidney disease. National Kidney and Urologic Diseases Information Clearinghouse. http://kidney.niddk.nih.gov/kudiseases/pubs/polycystic/. Accessed March 11, 2017.
- Chapman AB, et al. Course and treatment of autosomal dominant polycystic kidney disease. https://www.uptodate.com/home. Accessed March 11, 2017.
- Polycystic kidney disease. American Kidney Fund. http://www.kidneyfund.org/kidney-disease/other-kidney-conditions/polycystic-kidney-disease.html?&gclid=Cj0KEQiA3Y7GBRD29f-7kYuO1-ABEiQAodAvwGAsS7ELsM8hNXkbCPt3pE8hsRp-kijSf4UAs-ZmPVgaArPQ8P8HAQ. Accessed March 11, 2017.
- Bennett WM, et al. Extrarenal manifestations of autosomal dominant polycystic kidney disease. https://www.uptodate.com/home. Accessed March 11, 2017.
- Polycystic kidney disease. National Kidney Foundation. https://www.kidney.org/atoz/content/polycystic. Accessed March 11, 2017.
- Torres VE, et al. Diagnosis and screening for autosomal dominant polycystic kidney disease. https://www.uptodate.com/home. Accessed March 11, 2017.
- Albert CM, et al. Autosomal dominant polycystic kidney disease: The changing face of clinical management. The Lancet. 2015;385:1993.
- Rossetti S, et al. Identification of gene mutations in autosomal dominant polycystic kidney disease through targeted resequencing. Journal of the American Society of Nephrology. 2012;23:915.
- Torres VE, et al. Strategies targeting cAMP signaling in the treatment of polycystic kidney disease. Journal of the American Society of Nephrology. 2014; 25:18.
- Shoaf SE, et al. Pharmacokinetics and pharmacodynamics of Tolvaptan in autosomal dominat polycystic kidney disease: Phase 2 trials for dose selection in the pivotal phase 3 trial. The Journal of Clinical Pharmacology. In press. Accessed March 11, 2017.
- Hogan MC, et al. Somatostatin analog therapy for severe polycystic liver disease: Results after 2 years. Nephrology Dialysis Transplantation. 2012;27:3532.
- Riggin EA. Allscripts EPSi. Mayo Clinic, Rochester, Minn. Jan. 24, 2017.
Polycystic kidney disease